Article

Wet AMD 18-month data unveiled

The 18-month data of a proprietary epiretinal brachytherapy (NeoVista) for the treatment of wet age-related macular degeneration were made public at the recent Retina Society annual meeting.

Scottsdale, AZ-The 18-month data of a proprietary epiretinal brachytherapy (NeoVista) for the treatment of wet age-related macular degeneration (AMD) were made public at the recent Retina Society annual meeting.

The study, which was initiated to test the safety and efficacy of the therapy when used in conjunction with bevacizumab (Avastin, Genentech), showed a marked advancement in mean visual acuity results at month 18; a limited number of patients required additional injections of bevacizumab, according to the company.

"We're very delighted with the latest data from our phase II study, as not only did the visual acuity improve in our patients over the long-term, but very few patients received additional injections as well," said John N. Hendrick, president and chief executive officer of NeoVista.

The therapy applies a targeted dose of beta radiation to the leaking blood vessels that affect central vision, along with two injections of an anti-vascular endothelial growth factor agent. Preliminary data show that the radiation therapy can be safe for both the patient and the physician, and may be able to restore the patient’s vision.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
Shehzad Batliwala, DO, aka Dr. Shehz, discussed humanitarian ophthalmology and performing refractive surgery in low-resource, high-risk areas at the ASCRS Foundation Symposium.
(Image credit: Ophthalmology Times) ASCRS 2025: Advancing vitreous care with Inder Paul Singh, MD
(Image credit: Ophthalmology Times) The Residency Report: Study provides new insights into USH2A target end points
Lisa Nijm, MD, says preoperative osmolarity testing can manage patient expectations and improve surgical results at the 2025 ASCRS annual meeting
At the 2025 ASCRS Annual Meeting, Weijie Violet Lin, MD, ABO, shares highlights from a 5-year review of cross-linking complications
Maanasa Indaram, MD, is the medical director of the pediatric ophthalmology and adult strabismus division at University of California San Francisco, and spoke about corneal crosslinking (CXL) at the 2025 ASCRS annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Taylor Strange, DO, assesses early visual outcomes with femto-created arcuate incisions in premium IOL cases
(Image credit: Ophthalmology Times) ASCRS 2025: Neda Shamie, MD, shares her early clinical experience with the Unity VCS system
Patricia Buehler, MD, MPH, founder and CEO of Osheru, talks about the Ziplyft device for noninvasive blepharoplasty at the 2025 American Society of Cataract and Refractive Surgeons (ASCRS) annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Bonnie An Henderson, MD, on leveraging artificial intelligence in cataract refractive surgery
© 2025 MJH Life Sciences

All rights reserved.